<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029144</url>
  </required_header>
  <id_info>
    <org_study_id>A14-390</org_study_id>
    <nct_id>NCT02029144</nct_id>
  </id_info>
  <brief_title>Observational Study of Dydrogesterone in Cycle Regularization</brief_title>
  <official_title>Dydrogesterone in Cycle Regularization in Abnormal Uterine Bleeding - Ovulation Dysfunction (AUB-O) Patients: A Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dydrogesterone has been widely used worldwide for various gynecological and obstetric
      indications:

        -  Dydrogesterone is effective in cycle regulation treatment.

        -  Dydrogesterone is recognized as none interference to hypothalamus pituitary ovary (HPO)
           axis in the recommended dosage.

        -  Dydrogesterone might have non-negative effect on glucose and lipid metabolic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed as a prospective, non-interventional, observational study.
      Patients with irregular cycle diagnosed as AUB-O will be prescribed dydrogesterone as per
      physician's clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients reporting a regular cycle (defined as cycle duration≥21 and ≤ 35 days) at the end of cycle 3</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">114</enrollment>
  <condition>Observational Study</condition>
  <condition>Dydrogesterone</condition>
  <condition>Irregular Menstrual Cycle</condition>
  <condition>Abnormal Uterine Bleeding</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese women who is suffering from irregular menstrual cycle for at least 3 months and has
        been diagnosed as AUB-O
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 16 years or above with menses

          -  Patient who is suffering from irregular menstrual cycle for at least 3 months and has
             been diagnosed as AUB-O (irregular cycle is defined as cycle duration ＜ 21days or ＞35
             days)

          -  Physicians have decided to prescribe dydrogesterone 10mg for cycle regulation
             treatment, orally taking dydrogesterone 10mg twice daily, from day16 to day 25 of each
             cycle, being consecutive at least 3 cycles

          -  Patient who is willing to sign written authorization

        Exclusion Criteria:

          -  Hyperprolactinemia and thyroid dysfunction.

          -  Patient took cycle regulation treatment including oral contraceptives, sex hormone or
             glucocorticoid in the past 1 month

          -  Women with estrogen deficiency related symptom

          -  Patient who meets the contraindications listed in Chinese label of dydrogesterone

          -  Pregnant and lactating patients

          -  Patient who is not suitable for the study according to physician's discretion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhang Wei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

